ZYDUSLIFEPharmaceuticals
Zydus Lifesciences Ltd — Balance Sheet
₹871.20
+0.00%
Zydus Lifesciences Ltd Balance Sheet (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Equity Gross Minority Interest | 26.36K Cr | 22.10K Cr | 19.69K Cr | 19.05K Cr | — |
| Minority Interest | 2.41K Cr | 2.27K Cr | 2.17K Cr | 2.05K Cr | — |
| Stockholders Equity | 23.95K Cr | 19.83K Cr | 17.52K Cr | 17.00K Cr | — |
| Other Equity Interest | 23.85K Cr | 19.73K Cr | 17.41K Cr | 16.90K Cr | — |
| Retained Earnings | 24.56K Cr | 20.37K Cr | 17.19K Cr | 15.50K Cr | — |
| Additional Paid In Capital | 1.80 Cr | 1.80 Cr | 1.20 Cr | 0.00 | — |
| Capital Stock | 100.60 Cr | 100.60 Cr | 101.20 Cr | 102.40 Cr | — |
| Common Stock | 100.60 Cr | 100.60 Cr | 101.20 Cr | 102.40 Cr | — |
| Total Liabilities Net Minority Interest | 10.84K Cr | 7.18K Cr | 6.07K Cr | 8.74K Cr | — |
| Total Non Current Liabilities Net Minority Interest | 1.80K Cr | 1.84K Cr | 537.40 Cr | 902.20 Cr | — |
| Other Non Current Liabilities | 0.90 Cr | 1.80 Cr | — | 0.30 Cr | 1.00 Cr |
| Non Current Pension And Other Postretirement Benefit Plans | 383.90 Cr | 309.70 Cr | 271.80 Cr | 325.00 Cr | — |
| Non Current Deferred Revenue | 0.90 Cr | 1.80 Cr | 0.00 | 28.70 Cr | — |
| Non Current Deferred Taxes Liabilities | 512.60 Cr | 446.50 Cr | 194.40 Cr | 153.80 Cr | — |
| Long Term Debt And Capital Lease Obligation | 32.10 Cr | 25.10 Cr | 19.80 Cr | 378.20 Cr | — |
| Long Term Capital Lease Obligation | 32.10 Cr | 25.10 Cr | 19.80 Cr | 16.10 Cr | — |
| Long Term Provisions | 383.90 Cr | 309.70 Cr | 271.80 Cr | 325.00 Cr | — |
| Current Liabilities | 9.04K Cr | 5.34K Cr | 5.53K Cr | 7.84K Cr | — |
| Other Current Liabilities | 39.20 Cr | 39.60 Cr | 51.00 Cr | 34.50 Cr | — |
| Current Deferred Taxes Liabilities | 615.70 Cr | 372.00 Cr | 156.80 Cr | 41.80 Cr | — |
| Current Debt And Capital Lease Obligation | 3.18K Cr | 779.10 Cr | 1.18K Cr | 3.84K Cr | — |
| Current Capital Lease Obligation | 11.60 Cr | 10.50 Cr | 11.90 Cr | 8.80 Cr | — |
| Current Debt | 3.17K Cr | 768.60 Cr | 1.16K Cr | 3.83K Cr | — |
| Current Provisions | 451.40 Cr | 394.80 Cr | 365.40 Cr | 365.60 Cr | — |
| Payables | 2.60K Cr | 2.41K Cr | 2.40K Cr | 2.36K Cr | — |
| Other Payable | 286.40 Cr | 280.20 Cr | 269.00 Cr | 212.70 Cr | — |
| Dividends Payable | 4.00 Cr | 4.60 Cr | 4.80 Cr | 5.40 Cr | — |
| Total Tax Payable | 615.70 Cr | 372.00 Cr | 156.80 Cr | 41.80 Cr | — |
| Accounts Payable | 2.31K Cr | 2.13K Cr | 2.13K Cr | 2.14K Cr | — |
| Total Assets | 37.20K Cr | 29.28K Cr | 25.76K Cr | 27.80K Cr | — |
| Total Non Current Assets | 20.16K Cr | 17.78K Cr | 15.74K Cr | 15.53K Cr | — |
| Other Non Current Assets | 21.60 Cr | 21.00 Cr | 18.10 Cr | 14.40 Cr | — |
| Non Current Prepaid Assets | 200.30 Cr | 210.10 Cr | 210.30 Cr | 229.40 Cr | — |
| Non Current Deferred Taxes Assets | 2.34K Cr | 1.64K Cr | 1.26K Cr | 1.10K Cr | — |
| Investmentin Financial Assets | 380.60 Cr | 448.50 Cr | 738.90 Cr | 407.40 Cr | — |
| Available For Sale Securities | 68.10 Cr | 131.90 Cr | 286.10 Cr | 69.00 Cr | — |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | 237.40 Cr | 258.00 Cr | 266.30 Cr | 279.50 Cr | — |
| Trading Securities | 75.10 Cr | 58.60 Cr | 63.20 Cr | 58.90 Cr | — |
| Long Term Equity Investment | 1.18K Cr | 529.40 Cr | 457.60 Cr | 561.30 Cr | — |
| Investmentsin Joint Venturesat Cost | 1.14K Cr | 416.20 Cr | 416.60 Cr | 374.30 Cr | — |
| Investments In Other Ventures Under Equity Method | 40.80 Cr | 30.10 Cr | 41.00 Cr | 40.30 Cr | — |
| Investmentsin Subsidiariesat Cost | 0.00 | 83.10 Cr | 123.40 Cr | 146.70 Cr | — |
| Goodwill And Other Intangible Assets | 8.47K Cr | 7.88K Cr | 5.89K Cr | 6.49K Cr | — |
| Other Intangible Assets | 3.22K Cr | 2.61K Cr | 1.09K Cr | 1.13K Cr | — |
| Goodwill | 5.24K Cr | 5.27K Cr | 4.80K Cr | 5.36K Cr | — |
| Net PPE | 7.56K Cr | 7.05K Cr | 6.97K Cr | 6.56K Cr | — |
| Accumulated Depreciation | -5.62K Cr | -5.08K Cr | -4.50K Cr | -3.91K Cr | — |
| Gross PPE | 13.18K Cr | 12.13K Cr | 11.48K Cr | 10.47K Cr | — |
| Construction In Progress | 1.52K Cr | 1.25K Cr | 1.28K Cr | 800.90 Cr | — |
| Other Properties | 6.04K Cr | 5.80K Cr | 5.70K Cr | 5.76K Cr | — |
| Machinery Furniture Equipment | 8.65K Cr | 8.08K Cr | 7.50K Cr | 7.13K Cr | — |
| Buildings And Improvements | 2.37K Cr | 2.19K Cr | 2.07K Cr | 1.97K Cr | — |
| Land And Improvements | 642.40 Cr | 617.00 Cr | 625.80 Cr | 572.70 Cr | — |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Current Assets | 17.05K Cr | 11.50K Cr | 10.02K Cr | 12.26K Cr | — |
| Other Current Assets | 11.30 Cr | 17.50 Cr | 18.60 Cr | 4.80 Cr | — |
| Hedging Assets Current | 17.80 Cr | 280.30 Cr | 0.00 | — | — |
| Assets Held For Sale Current | 0.00 | 81.60 Cr | 8.20 Cr | 166.20 Cr | — |
| Restricted Cash | 4.00 Cr | 4.60 Cr | 4.80 Cr | 5.40 Cr | — |
| Prepaid Assets | 656.20 Cr | 719.00 Cr | 729.60 Cr | 1.32K Cr | — |
| Inventory | 3.94K Cr | 3.44K Cr | 3.41K Cr | 3.72K Cr | — |
| Other Inventories | 180.50 Cr | 164.90 Cr | 228.30 Cr | 294.80 Cr | — |
| Finished Goods | 1.78K Cr | 1.65K Cr | 1.55K Cr | 1.86K Cr | — |
| Work In Process | 661.90 Cr | 605.50 Cr | 459.70 Cr | 383.90 Cr | — |
| Raw Materials | 1.32K Cr | 1.02K Cr | 1.18K Cr | 1.18K Cr | — |
| Other Receivables | 485.80 Cr | 265.80 Cr | 154.20 Cr | 153.00 Cr | — |
| Taxes Receivable | 74.10 Cr | 90.80 Cr | 64.30 Cr | 71.30 Cr | — |
| Accounts Receivable | 4.02K Cr | 5.22K Cr | 4.42K Cr | 3.34K Cr | — |
| Allowance For Doubtful Accounts Receivable | -73.70 Cr | -45.60 Cr | -25.00 Cr | -23.60 Cr | — |
| Gross Accounts Receivable | 4.10K Cr | 5.27K Cr | 4.44K Cr | 3.36K Cr | — |
| Cash Cash Equivalents And Short Term Investments | 7.83K Cr | 1.38K Cr | 1.21K Cr | 3.48K Cr | — |
| Other Short Term Investments | 7.00K Cr | 966.70 Cr | 718.80 Cr | 2.82K Cr | — |
| Cash And Cash Equivalents | 826.80 Cr | 413.00 Cr | 487.80 Cr | 657.80 Cr | — |
| Cash Financial | 826.80 Cr | 413.00 Cr | 487.80 Cr | 657.80 Cr | — |
| Ordinary Shares Number | 100.62 Cr | 100.62 Cr | 101.22 Cr | 102.37 Cr | — |
| Share Issued | 100.62 Cr | 100.62 Cr | 101.22 Cr | 102.37 Cr | — |
| Net Debt | 2.34K Cr | 355.60 Cr | 675.40 Cr | 3.54K Cr | — |
| Total Debt | 3.21K Cr | 804.20 Cr | 1.19K Cr | 4.22K Cr | — |
| Tangible Book Value | 15.49K Cr | 11.95K Cr | 11.62K Cr | 10.51K Cr | — |
| Invested Capital | 27.12K Cr | 20.60K Cr | 18.68K Cr | 21.20K Cr | — |
| Working Capital | 8.00K Cr | 6.16K Cr | 4.49K Cr | 4.42K Cr | — |
| Net Tangible Assets | 15.49K Cr | 11.95K Cr | 11.62K Cr | 10.51K Cr | — |
| Capital Lease Obligations | 43.70 Cr | 35.60 Cr | 31.70 Cr | 24.90 Cr | — |
| Common Stock Equity | 23.95K Cr | 19.83K Cr | 17.52K Cr | 17.00K Cr | — |
| Total Capitalization | 23.95K Cr | 19.83K Cr | 17.52K Cr | 17.36K Cr | — |
| Treasury Shares Number | — | 0.00 | — | — | — |
| Long Term Debt | — | 0.00 | 0.00 | 362.10 Cr | 609.50 Cr |
| Financial Assets | — | 0.00 | 182.70 Cr | 171.40 Cr | 159.00 Cr |
| Held To Maturity Securities | — | 351.60 Cr | 123.30 Cr | 280.10 Cr | 10.20 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Zydus Lifesciences Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.